Why Bio-Rad Laboratories, Inc. (BIO) stock moved
Bio-Rad Laboratories, Inc. (BIO) shares fell 0.2% to $351.92 as of August 10, 2026, a slight decline from the prior close of $352.47. BestStocks flagged the session as a major change for BIO. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for BIO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
BIO fell 0.2% to $351.92
BIO fell 0.2% in its latest session, moving from $352.47 to $351.92.
What it means for Bio-Rad Laboratories, Inc. investors
For Bio-Rad Laboratories, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Bio-Rad Laboratories, Inc. (BIO) moved +3.92% from $339.18 to $352.47 on 2026-08-07, reaching a new 30-day high; Bio-Rad Laboratories, Inc. (BIO) moved +2.13% from $340.61 to $347.86 on 2026-08-05, reaching a new 30-day high. Weighing against that: Material negative event; Negative session, down 0.2%. Wall Street's consensus price target sits at $345.00, implying -2.0% downside from $351.92. BestStocks rates the overall signal quality weak (27/100). With earnings roughly 80 days out, the next report is the most likely near-term test of the move.
BIO price reaction
BIO last traded at $351.92, down $0.55 (-0.16%) from the previous close of $352.47. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $295.73 and $352.47, and it currently sits about 99% of the way up that band.
Bullish and bearish analyst opinions on Bio-Rad Laboratories, Inc. (BIO)
The consensus analyst price target on Bio-Rad Laboratories, Inc. (BIO) is $345.00, 2.0% below the recent $351.92. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BIO line up.
The bullish case
- The Street's most bullish target is $390.00 (+10.8%).
- Bio-Rad Laboratories, Inc. (BIO) moved +3.92% from $339.18 to $352.47 on 2026-08-07, reaching a new 30-day high.
The bearish case
- The consensus analyst price target of $345.00 sits 2.0% below the recent $351.92, so the average target sees limited room to run.
- The most bearish analyst target is $310.00 (-11.9%).
- Material negative event.
- Negative session, down 0.2%.
- BIO moved -2.95% from $292.50 to $283.86 on 2026-07-08.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for BIO
Frequently asked questions about BIO
Why did Bio-Rad Laboratories, Inc. (BIO) stock move?
BIO fell 0.2% to $351.92. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did BIO stock fall?
BIO lost 0.16% ($0.55) versus the prior close of $352.47, last trading at $351.92 on 0.2× average volume.
When is Bio-Rad Laboratories, Inc.'s next earnings date?
BIO's next earnings report is estimated for 2026-10-29 — about 80 days away.
What is the analyst price target for BIO?
The consensus analyst price target for BIO is $345.00, about 2.0% below the current $351.92. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.
How BestStocks tracks BIO
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared BIO-specific materiality thresholds, triggering an evidence check. It draws on 13 tracked change events for BIO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.